UK markets closed
NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.70 +0.22 (+0.28%) GOLD FUTURES
2,320.90 -10.30 (-0.44%) DOW
38,921.90 +69.63 (+0.18%) Bitcoin GBP
50,652.27 +35.02 (+0.07%)
Actinium Pharmaceuticals, Inc. (ATNM)
NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 01:10PM EDT. Market open.
| Previous close | 8.84 |
| Open | 8.88 |
| Bid | 8.48 x 800 |
| Ask | 8.55 x 800 |
| Day's range | 8.45 - 8.94 |
| 52-week range | 4.00 - 9.86 |
| Volume | |
| Avg. volume | 391,918 |
| Market cap | 253.669M |
| Beta (5Y monthly) | 0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.